<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40629329</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>09</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1741-7015</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>09</Day></PubDate></JournalIssue><Title>BMC medicine</Title><ISOAbbreviation>BMC Med</ISOAbbreviation></Journal><ArticleTitle>Firesorb bioresorbable scaffold for de novo coronary artery disease: 1-year clinical outcomes.</ArticleTitle><Pagination><StartPage>419</StartPage><MedlinePgn>419</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">419</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12916-025-04254-0</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The first-generation bioresorbable scaffolds (BRS) have been associated with higher rates of device-related adverse outcomes in comparison to everolimus-eluting stents. We aimed to evaluate the efficacy and safety of the thinner-strut (100/125&#xa0;&#x3bc;m) poly-L-lactic acid-based sirolimus-eluting Firesorb BRS in patients with de novo coronary lesions.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patient-level data derived from 1205 patients in the FUTURE-II RCT (n&#x2009;=&#x2009;215) and FUTURE-III registry (n&#x2009;=&#x2009;990) were prospectively collected, pooled, and analyzed. The primary endpoint of 1-year target lesion failure (TLF) was defined as a composite of cardiac death, target vessel myocardial infarction, or ischemia-driven target lesion revascularization. The patient-oriented composite endpoint (POCE) of all-cause death, any myocardial infarction, or any revascularization was also analyzed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">At 1-year follow-up, the cumulative rate of TLF was 1.67%, with an upper 95% confidence interval of 2.57%, significantly lower than the objective performance criterion goal of 6.6% (P&#x2009;&lt;&#x2009;0.001). The rate of single TLF components was 0.42% for cardiac death, 0.92% for target vessel myocardial infarction, and 0.42% for ischemia-driven target lesion revascularization. The cumulative rate of POCE at 1&#xa0;year was 3.34%. No patient experienced definite or probable device thrombosis during 1-year follow-up.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This pooled, patient-level analysis indicates that the thinner strut Firesorb BRS exhibits promising 1-year efficacy and safety profiles with regard to TLF. However, our findings are only applicable to non-complex lesions; large-scale randomized clinical trials powered to assess clinical endpoints are necessary to evaluate the strategy of Firesorb BRS compared to drug-eluting stents.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">ClinicalTrials.gov Identifier: NCT02890160 and NCT03660202.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory of Transvascular Implantation Devices, Hangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Heart Regeneration and Repair Key Laboratory of Zhejiang Province, Hangzhou, 310009, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Transvascular Implantation Devices Research Institute, Binjiang District, Hang Zhou, 310053, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Changling</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory of Transvascular Implantation Devices, Hangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Heart Regeneration and Repair Key Laboratory of Zhejiang Province, Hangzhou, 310009, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Transvascular Implantation Devices Research Institute, Binjiang District, Hang Zhou, 310053, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Delong</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Cardiology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory of Transvascular Implantation Devices, Hangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Heart Regeneration and Repair Key Laboratory of Zhejiang Province, Hangzhou, 310009, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Transvascular Implantation Devices Research Institute, Binjiang District, Hang Zhou, 310053, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cardiology, National Center for Cardiovascular Diseases, Fu Wai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Zhanqian</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Inner Mongolia Autonomous Region People's Hospital, Hohhot, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ping</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Cardiology, The First People's Hospital of Yulin, Yulin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gan</LastName><ForeName>Lijun</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Affiliated Hospital of Jining Medical University, Jining, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yundai</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Chinese PLA General Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Hui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Daqing Oilfield General Hospital, Daqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jia</LastName><ForeName>Shaobin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiology, General Hospital of Ningxia Medical University, Ningxia, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Shenghu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Northern Jiangsu People's Hospital, Yangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Wen</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Xuzhou Central Hospital, Xuzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Runlin</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Cardiology, National Center for Cardiovascular Diseases, Fu Wai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. gaorunlin@citmd.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jianan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. wangjianan111@zju.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory of Transvascular Implantation Devices, Hangzhou, China. wangjianan111@zju.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Heart Regeneration and Repair Key Laboratory of Zhejiang Province, Hangzhou, 310009, China. wangjianan111@zju.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Transvascular Implantation Devices Research Institute, Binjiang District, Hang Zhou, 310053, China. wangjianan111@zju.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>FUTURE III Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03660202</AccessionNumber><AccessionNumber>NCT02890160</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>2023ZD0504100</GrantID><Agency>National Science and Technology Major Project</Agency><Country/></Grant><Grant><GrantID>KY012024002</GrantID><Agency>Transvascular Implantation Devices Research Institute</Agency><Country/></Grant><Grant><GrantID>82170332</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Med</MedlineTA><NlmUniqueID>101190723</NlmUniqueID><ISSNLinking>1741-7015</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003324" MajorTopicYN="Y">Coronary Artery Disease</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020341" MajorTopicYN="Y">Absorbable Implants</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054855" MajorTopicYN="Y">Drug-Eluting Stents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054457" MajorTopicYN="Y">Tissue Scaffolds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062645" MajorTopicYN="N">Percutaneous Coronary Intervention</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bioresorbable scaffolds</Keyword><Keyword MajorTopicYN="N">Coronary artery diseases</Keyword><Keyword MajorTopicYN="N">Percutaneous coronary intervention</Keyword><Keyword MajorTopicYN="N">Target lesion failure</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: Our study was conducted in accordance with the Helsinki Declaration and was approved by the ethical review board of all participated centers (approval number: I2019001617 for The Second Affiliated Hospital, Zhejiang University School of Medicine, 2016-772 for Fu Wai Hospital, 2019-020 for Chinese PLA General Hospital, 2019-QX-011 for General Hospital of Ningxia Medical University, TZS-2021-002-01 for The First People&#x2019;s Hospital of Yulin, XZXY-LQ-20200109-005 for Xuzhou Central Hospital, 2020-002-01 for Inner Mongolia Autonomous Region People&#x2019;s Hospital, 2020-01-C for Affiliated Hospital of Jining Medical University, 2020-05-02 for Daqing Oilfield General Hospital, and 2020007 for Northern Jiangsu People&#x2019;s Hospital). Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>9</Day><Hour>0</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>8</Day><Hour>23</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40629329</ArticleId><ArticleId IdType="pmc">PMC12239348</ArticleId><ArticleId IdType="doi">10.1186/s12916-025-04254-0</ArticleId><ArticleId IdType="pii">10.1186/s12916-025-04254-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79(2):e21&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pubmed">34895950</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue T, Croce K, Morooka T, Sakuma M, Node K, Simon DI. Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis. JACC Cardiovasc Interv. 2011;4(10):1057&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3341937</ArticleId><ArticleId IdType="pubmed">22017929</ArticleId></ArticleIdList></Reference><Reference><Citation>Otsuka F, Byrne RA, Yahagi K, Mori H, Ladich E, Fowler DR, et al. Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment. Eur Heart J. 2015;36(32):2147&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">25994755</ArticleId></ArticleIdList></Reference><Reference><Citation>Otsuka F, Pacheco E, Perkins LE, Lane JP, Wang Q, Kamberi M, et al. Long-term safety of an everolimus-eluting bioresorbable vascular scaffold and the cobalt-chromium XIENCE V stent in a porcine coronary artery model. Circ Cardiovasc Interv. 2014;7(3):330&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">24895447</ArticleId></ArticleIdList></Reference><Reference><Citation>Serruys PW, Chevalier B, Dudek D, Cequier A, Carri&#xe9; D, Iniguez A, et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet. 2015;385(9962):43&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">25230593</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellis SG, Kereiakes DJ, Metzger DC, Caputo RP, Rizik DG, Teirstein PS, et al. Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. N Engl J Med. 2015;373(20):1905&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">26457558</ArticleId></ArticleIdList></Reference><Reference><Citation>Serruys PW, Ormiston J, van Geuns RJ, de Bruyne B, Dudek D, Christiansen E, et al. A Polylactide Bioresorbable Scaffold Eluting Everolimus for Treatment of Coronary Stenosis: 5-Year Follow-Up. J Am Coll Cardiol. 2016;67(7):766&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">26892411</ArticleId></ArticleIdList></Reference><Reference><Citation>Power DA, Camaj A, Kereiakes DJ, Ellis SG, Gao R, Kimura T, et al. Early and Late Outcomes With the Absorb Bioresorbable Vascular Scaffold: Final Report From the ABSORB Clinical Trial Program. JACC Cardiovasc Interv. 2025;18(1):1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">39814482</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone GW, Kimura T, Gao R, Kereiakes DJ, Ellis SG, Onuma Y, et al. Time-Varying Outcomes With the Absorb Bioresorbable Vascular Scaffold During 5-Year Follow-up: A Systematic Meta-analysis and Individual Patient Data Pooled Study. JAMA Cardiol. 2019;4(12):1261&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6777269</ArticleId><ArticleId IdType="pubmed">31561250</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaji K, Ueki Y, Souteyrand G, Daemen J, Wiebe J, Nef H, et al. Mechanisms of Very Late Bioresorbable Scaffold Thrombosis: The INVEST Registry. J Am Coll Cardiol. 2017;70(19):2330&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">29096803</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenekecioglu E, Torii R, Katagiri Y, Asano T, Modolo R, Miyazaki Y, et al. Early strut protrusion and late neointima thickness in the Absorb bioresorbable scaffold: a serial wall shear stress analysis up to five years. EuroIntervention. 2019;15(4):e370&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">29969424</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng JF, Xi ZW, Li Y, Li JN, Qiu H, Hu XY, et al. Long-term safety and absorption assessment of a novel bioresorbable nitrided iron scaffold in porcine coronary artery. Bioact Mater. 2022;17:496&#x2013;505.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8976101</ArticleId><ArticleId IdType="pubmed">35415293</ArticleId></ArticleIdList></Reference><Reference><Citation>Varcoe RL, DeRubertis BG, Kolluri R, Krishnan P, Metzger DC, Bonaca MP, et al. Drug-Eluting Resorbable Scaffold versus Angioplasty for Infrapopliteal Artery Disease. N Engl J Med. 2024;390(1):9&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">37888915</ArticleId></ArticleIdList></Reference><Reference><Citation>Song L, Sun Z, Guan C, Yan H, Yu M, Cui J, et al. First-in-man study of a thinner-strut sirolimus-eluting bioresorbable scaffold (FUTURE-I): Three-year clinical and imaging outcomes. Catheter Cardiovasc Interv. 2020;95(Suppl 1):648&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">31909884</ArticleId></ArticleIdList></Reference><Reference><Citation>Song L, Xu B, Chen Y, Zhou Y, Jia S, Zhong Z, et al. Thinner Strut Sirolimus-Eluting BRS Versus EES in Patients With Coronary Artery Disease: FUTURE-II Trial. JACC Cardiovasc Interv. 2021;14(13):1450&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">34238555</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone GW, Abizaid A, Onuma Y, Seth A, Gao R, Ormiston J, et al. Effect of Technique on Outcomes Following Bioresorbable Vascular Scaffold Implantation: Analysis From the ABSORB Trials. J Am Coll Cardiol. 2017;70(23):2863&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">29100704</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortega-Paz L, Capodanno D, Gori T, Nef H, Latib A, Caramanno G, et al. Predilation, sizing and post-dilation scoring in patients undergoing everolimus-eluting bioresorbable scaffold implantation for prediction of cardiac adverse events: development and internal validation of the PSP score. EuroIntervention. 2017;12(17):2110&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">28246060</ArticleId></ArticleIdList></Reference><Reference><Citation>Gori T, Weissner M, G&#xf6;nner S, Wendling F, Ullrich H, Ellis S, et al. Characteristics, Predictors, and Mechanisms of Thrombosis in Coronary Bioresorbable Scaffolds: Differences Between Early and Late Events. JACC Cardiovasc Interv. 2017;10(23):2363&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">29216999</ArticleId></ArticleIdList></Reference><Reference><Citation>Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD. Fourth Universal Definition of Myocardial Infarction (2018). J Am Coll Cardiol. 2018;72(18):2231&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">30153967</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone GW, Gao R, Kimura T, Kereiakes DJ, Ellis SG, Onuma Y, et al. 1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis. Lancet. 2016;387(10025):1277&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">26825231</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu B, Zhao Y, Yang Y, Zhang R, Li H, Ma C, et al. Safety and efficacy of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent for the treatment of de novo coronary lesions: 12-month results from the TARGET II trial. Chin Med J (Engl). 2014;127(6):1027&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">24622429</ArticleId></ArticleIdList></Reference><Reference><Citation>Taglieri N, Bruno AG, Ghetti G, Marrozzini C, Saia F, Gali&#xe9; N, Palmerini T. Target Lesion Failure With Current Drug-Eluting Stents: Evidence From a Comprehensive Network Meta-Analysis. JACC Cardiovasc Interv. 2020;13(24):2868&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">33357524</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi KH, Song YB, Lee JM, Park TK, Yang JH, Hahn JY, et al. Differential Long-Term Effects of First- and Second-Generation DES in Patients With Bifurcation Lesions Undergoing PCI. JACC Asia. 2021;1(1):68&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9627880</ArticleId><ArticleId IdType="pubmed">36338362</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone GW, Ellis SG, Gori T, Metzger DC, Stein B, Erickson M, et al. Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial. Lancet. 2018;392(10157):1530&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">30266412</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu K, Fu G, Xu B, Zhou Y, Su X, Liu H, et al. Safety and efficacy of the novel sirolimus-eluting bioresorbable scaffold for the treatment of de novo coronary artery disease: One-year results from a prospective patient-level pooled analysis of NeoVas trials. Catheter Cardiovasc Interv. 2019;93(S1):832&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">30888736</ArticleId></ArticleIdList></Reference><Reference><Citation>Taniwaki M, Radu MD, Zaugg S, Amabile N, Garcia-Garcia HM, Yamaji K, et al. Mechanisms of Very Late Drug-Eluting Stent Thrombosis Assessed by Optical Coherence Tomography. Circulation. 2016;133(7):650&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">26762519</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmerini T, Biondi-Zoccai G, Della Riva D, Stettler C, Sangiorgi D, D&#x2019;Ascenzo F, et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet. 2012;379(9824):1393&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pubmed">22445239</ArticleId></ArticleIdList></Reference><Reference><Citation>Collet C, Asano T, Miyazaki Y, Tenekecioglu E, Katagiri Y, Sotomi Y, et al. Late thrombotic events after bioresorbable scaffold implantation: a systematic review and meta-analysis of randomized clinical trials. Eur Heart J. 2017;38(33):2559&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">28430908</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerkmeijer LSM, Renkens MPL, Tijssen RYG, Hofma SH, van der Schaaf RJ, Arkenbout EK, et al. Long-term clinical outcomes of everolimus-eluting bioresorbable scaffolds versus everolimus-eluting stents: final five-year results of the AIDA randomised clinical trial. EuroIntervention. 2022;17(16):1340&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9743247</ArticleId><ArticleId IdType="pubmed">34483094</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherman RB, Woodcock J, Norden J, Grandinetti C, Temple RJ. New FDA regulation to improve safety reporting in clinical trials. N Engl J Med. 2011;365(1):3&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">21651388</ArticleId></ArticleIdList></Reference><Reference><Citation>Zabor EC, Kaizer AM, Hobbs BP. Randomized Controlled Trials. Chest. 2020;158(1s):S79-s87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8176647</ArticleId><ArticleId IdType="pubmed">32658656</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein CE, Weijer C, Brehaut JC, Fergusson DA, Grimshaw JM, Horn AR, Taljaard M. Ethical issues in pragmatic randomized controlled trials: a review of the recent literature identifies gaps in ethical argumentation. BMC Med Ethics. 2018;19(1):14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5827974</ArticleId><ArticleId IdType="pubmed">29482537</ArticleId></ArticleIdList></Reference><Reference><Citation>Erlinge D, Andersson J, Fr&#xf6;bert O, T&#xf6;rnerud M, Hamid M, Kellerth T, et al. Bioadaptor implant versus contemporary drug-eluting stent in percutaneous coronary interventions in Sweden (INFINITY-SWEDEHEART): a single-blind, non-inferiority, registry-based, randomised controlled trial. Lancet. 2024;404(10464):1750&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">39481425</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura M, Suzuki N, Fujii K, Furuya J, Kawasaki T, Kimura T, et al. The Absorb GT1 Bioresorbable Vascular Scaffold System - 5-Year Post-Market Surveillance Study in Japan. Circ J. 2024;88(6):863&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">38479861</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SY, Kang DY, Hong SJ, Ahn JM, Ahn CM, Park DW, et al. Optical Coherence Tomography for Coronary Bioresorbable Vascular Scaffold Implantation: A Randomized Controlled Trial. Circ Cardiovasc Interv. 2020;13(1): e008383.</Citation><ArticleIdList><ArticleId IdType="pubmed">32525410</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>